文献速递糖尿病

低剂量达西胰高血糖素对比口服葡萄糖预防1型糖尿病患者胰岛素诱导低血糖:一项2期随机三臂交叉研究

Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover Study.
PubMed 文献 · Diabetes Care · 2022-01-01

本研究为2期随机三臂交叉研究,纳入20例使用每日多次注射或胰岛素泵治疗的1型糖尿病患者,比较低剂量皮下达西胰高血糖素(80微克、120微克)与15克口服葡萄糖在预防胰岛素诱导低血糖方面的疗效。结果显示,达西胰高血糖素可安全有效地预防低血糖,且升糖速度较口服葡萄糖更快。

要点

  • 达西胰高血糖素80微克和120微克组低血糖发生率分别为5例和4例,口服葡萄糖组为10例。
  • 达西胰高血糖素组血糖升高1.1 mmol/L的中位时间均为15分钟,快于口服葡萄糖组的30分钟。
  • 达西胰高血糖素给药后恶心发生例数在数值上较高,但无统计学显著差异。

核心结论

  • 低剂量达西胰高血糖素可安全有效地预防胰岛素诱导的低血糖,且升糖速度较口服葡萄糖更快。

研究设计与样本

  • 2期随机三臂交叉研究,纳入20例使用每日多次注射或胰岛素泵治疗的1型糖尿病成人患者。

主要发现

  • 低血糖(<3.9 mmol/L)发生例数:口服葡萄糖组10例,达西胰高血糖素80微克组5例(对比口服葡萄糖P=0.096),达西胰高血糖素120微克组4例(对比口服葡萄糖P=0.034)。
  • 低血糖(<3.9 mmol/L)时间占比:口服葡萄糖组14%,达西胰高血糖素80微克组7%,达西胰高血糖素120微克组6%(P=0.273)。
  • 血糖升高1.1 mmol/L的中位时间(95%CI):口服葡萄糖组30(25-50)分钟,达西胰高血糖素80微克组15(15-20)分钟(对比口服葡萄糖P=0.006),达西胰高血糖素120微克组15(15-20)分钟(对比口服葡萄糖P=0.003)。
  • 达西胰高血糖素给药后恶心发生例数在数值上较高,但无统计学显著差异;视觉模拟量表评估的不良反应在各干预间无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the efficacy of low-dose subcutaneous dasiglucagon with oral glucose for prevention of insulin-induced hypoglycemia in people with type 1 diabetes. RESEARCH DESIGN AND METHODS: Twenty adults with type 1 diabetes using multiple daily injection or insulin pump therapy completed a phase 2, randomized, three-arm crossover study. On each study visit, an individualized subcutaneous insulin bolus was administered aiming for a plasma glucose (PG) concentration of 3.0 mmol/L (54 mg/dL). When a PG concentration of 4.5 mmol/L (81 mg/dL) was reached, 15 g oral glucose (CHO) from dextrose tablets, 80 µg dasiglucagon (D80), or 120 µg dasiglucagon (D120) was administered. PG was measured frequently for the following 180 min. RESULTS: Hypoglycemia (<3.9 mmol/L [70 mg/dL]) occurred in 10 participants after CHO, in 5 after D80, and in 4 after D120 (CHO vs. D80, P = 0.096; CHO vs. D120, P = 0.034). Time spent in hypoglycemia (<3.9 mmol/L [70 mg/dL]) was 14%, 7%, and 6% for CHO, D80, and D120, respectively (P = 0.273). The median time (95% CI) from intervention to first increase in PG of 1.1 mmol/L (20 mg/dL) was 30 (25-50), 15 (15-20), and 15 (15-20) minutes for CHO, D80, and D120, respectively (CHO vs. D80, P = 0.006; CHO vs. D120, P = 0.003). Episodes of nausea were numerically, but not significantly, higher after dasiglucagon administration. No significant differences in visual analog scale-assessed adverse effects were observed between interventions. CONCLUSIONS: Low-dose dasiglucagon safely and effectively prevented insulin-induced hypoglycemia with a faster glucose-elevating profile than oral glucose.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Laugesen C, Ranjan AG, Schmidt S, et al. Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover Study. Diabetes Care. 2022. PMID: 35475907. doi:10.2337/dc21-2304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。